Adaptive Biotechnologies Corp
As-reported results for the 10 quarters ended Mar 31, 2024 to Jun 30, 2026
ADAPTIVE BIOTECHNOLOGIES CORP (ADPT)'s financial overview covers its 10 most recent reported quarters, with quarter-end dates from 2024-03-31 to 2026-06-30. Quarterly revenue ranged from USD 41.87M to USD 93.97M over the displayed quarters. The company reported positive net income in 1 of 10 quarters with available figures. In the latest quarter, the company reported revenue of USD 71.55M and diluted earnings per share of USD -0.25/share.
1Trends10 quarters · Mar ’24 to Jun ’26
2Income statementUSD, as reported
| Metric | Jun ’26 | Mar ’26 | Dec ’25 | Sep ’25 |
|---|---|---|---|---|
| Revenue | $71.55M | $70.87M | $71.68M | $93.97M |
| Cost of revenue | $20.16M | $18.71M | $18.22M | $18.16M |
| Gross profit | $51.39M | $52.17M | $53.46M | $75.82M |
| Operating expenses | $67.16M | $71.37M | $66.23M | $65.53M |
| Research and development | $19.15M | $23.62M | $21.76M | $23.67M |
| Selling, general and administrative | $47.58M | $47.33M | $44.04M | $41.43M |
| Operating income | −$15.77M | −$19.21M | −$12.77M | $10.29M |
| Interest expense | $2.69M | $2.89M | $2.95M | $2.97M |
| Income before tax | −$39.79M | −$20.03M | −$13.58M | $9.55M |
| Income tax expense | $0 | $0 | $0 | $0 |
| Net income | −$39.79M | −$20.03M | −$13.58M | $9.55M |
| Net income attributable to common shareholders | −$39.79M | −$20.03M | −$13.58M | $9.55M |
| EBIT | −$37.09M | −$17.14M | −$10.63M | $12.52M |
| EBITDA | −$32.27M | −$11.86M | −$5.06M | $18.27M |
| Basic earnings per shareUSD/share | -0.25 | -0.13 | -0.09 | 0.06 |
| Diluted earnings per shareUSD/share | -0.25 | -0.13 | -0.09 | 0.06 |
| Weighted-average basic sharesshares | 159.9M | 155.5M | 153.1M | 152.4M |
| Weighted-average diluted sharesshares | 159.9M | 155.5M | 153.1M | 163.2M |
3Balance sheetUSD, as reported
| Metric | Jun ’26 | Mar ’26 | Dec ’25 | Sep ’25 |
|---|---|---|---|---|
| Total assets | $640.68M | $505.94M | $512.74M | $490.61M |
| Current assets | $420.56M | $291.81M | $300.19M | $281.44M |
| Cash and cash equivalents | $169.87M | $77.58M | $70.5M | $55.03M |
| Total liabilities | $490.02M | $281.7M | $287.74M | $286.36M |
| Current liabilities | $87.71M | $87.01M | $89.92M | $83.36M |
| Total debt | $410.5M | $208.18M | $210.36M | $213.64M |
| Current debt | $8.82M | $14.32M | $13.56M | $11.87M |
| Equity attributable to parent | $142.91M | $216.34M | $218.79M | $204.44M |
4Cash flowUSD, as reported
| Metric | Jun ’26 | Mar ’26 | Dec ’25 | Sep ’25 |
|---|---|---|---|---|
| Operating cash flow | −$6.4M | −$9.54M | $2.06M | −$7.13M |
| Investing cash flow | −$43.48M | $9.14M | −$8.25M | $17.28M |
| Financing cash flow | $142.19M | $7.5M | $21.66M | $1.68M |
| Net capital expenditures (acquisitions and disposals) | $1.18M | $796K | $636K | $409K |
| Free cash flow | −$7.58M | −$10.33M | $1.42M | −$7.54M |
| Stock-based compensation | $11.12M | $11.93M | $12.72M | $13.26M |
5About these figures
Quarterly operating cash flow ranged from USD -38.35M to USD 2.06M over the displayed quarters. At the latest quarter-end, 2026-06-30, the company reported cash and cash equivalents of USD 169.87M and total debt of USD 410.50M. The tables below compare income statements, balance sheets and cash flows across all 10 quarters, with individual quarterly results available for further detail.
Figures are as reported in the company's quarterly filings for its 10 most recent reported quarters, up to 10 quarters per listing, newest first. Each quarter reflects the latest filed version of that quarter's statements; restated figures replace the originally reported ones. Per-share amounts are shown per share and share counts are weighted averages for the quarter. A dash marks a metric the company did not report for that quarter.